You are here: Home ยป Archives for NASDAQ

Montana Technologies Announces Memorandum of Understanding with TenX Investment to Deploy AirJoule® for Water Security and Sustainability in the United Arab Emirates

RONAN, Mont., Aug. 15, 2024 (GLOBE NEWSWIRE) — Montana Technologies Corporation (NASDAQ: AIRJ) (“Montana Technologies” or the “Company”), the developer of the transformational AirJoule® technology for atmospheric water generation, is pleased to announce the signing of a Memorandum of Understanding (“MOU”) with TenX Investment in Energy Enterprises & Management Co. LLC (“TenX”) to address water security and energy efficiency opportunities in the United Arab Emirates (“UAE”).

The collaboration between Montana Technologies and TenX aims to leverage AirJoule®’s cutting–edge technology to generate pure distilled water from air and reduce energy consumption for air conditioning, significantly enhancing water security and energy sustainability in the UAE. The Company and TenX will explore options to deploy AirJoule® units with initial installations focusing on critical infrastructure and community water needs.

“We are excited to work with TenX for this international deployment of AirJoule® units,” said Ramdas Rao, President, International of Montana Technologies. “The UAE has been at the forefront of adopting transformative technologies that enable sustainable development and responsible decarbonization. Along with our strategic investors including Transition Equity Partners (“TEP”), GE Vernova, and Carrier Corporation, among others, we look forward to optimizing our initial international rollout and operations in the UAE and working to enable water security and energy efficient comfort cooling in high growth markets around the world.”

Pat Eilers, Executive Chairman of Montana Technologies and founder of TEP, said, “TenX’s expertise and mission alignment in water security and sustainability projects makes them an ideal partner for deploying AirJoule in the UAE with a pathway towards further collaboration on local manufacturing and distribution in the future.”

Montana Technologies, through its 50/50 joint venture with GE Vernova, is commercializing AirJoule® atmospheric water generators that harvest water from both humid and arid atmospheres, producing pure distilled water and dehumidified air. AirJoule® units utilize metal organic framework coated contactors to extract water from air in a highly efficient and scalable process.

Matt Jore, CEO of Montana Technologies, said, “Since demonstrating the AirJoule® unit at COP 28 in Dubai in late 2023, there has been strong interest in the technology from customers across the world. AirJoule®’s ground–breaking advances in water harvesting and dehumidification will help to improve potable water access and security to millions of people in the region and beyond.”

TenX Investment, with its mission to bring the best international energy solutions to the UAE and MENA region, is currently focused on projects that enhance water security, energy efficiency, and sustainability. This MOU aligns with TenX’s strategy of investing in innovative technologies that provide substantial environmental and economic benefits. By integrating AirJoule® into their portfolio, TenX aims to offer sustainable water and energy solutions that reinforce their commitment to driving efficiency and sustainability.

Abdulrahman Al–Suwaidi, Managing Director at TenX Investment, commented: “We are proud to partner with Montana Technologies and look forward to investing in and deploying their innovative AirJoule® technology both in the UAE and internationally. This collaboration aligns perfectly with the UAE government's initiative to drive the private sector towards green and sustainable solutions, ensuring water security for future generations. Our joint efforts will significantly contribute to transforming the region's approach to water management and energy efficiency.”

Husain Al Awadhi, Managing Director at TenX Investment, added: “The UAE government has allocated over AED 20 billion1 towards water security and sustainable energy projects as part of its Vision 2030 strategy. By integrating Montana Technologies' AirJoule® systems, we aim to enhance the region's water generation capabilities and reduce energy consumption. This collaboration will not only help meet the growing demand for water and energy but also support the UAE's ambitious targets for sustainability and environmental stewardship. Together, we are committed to delivering impactful solutions that address the critical challenges of water scarcity and energy efficiency.”

  1. 1 USD = 3.67 AED

About Montana Technologies Corporation

Montana Technologies Corporation (NASDAQ: AIRJ) is the developer of AirJoule®, an atmospheric thermal energy and water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. Designed to reduce energy consumption and generate material cost efficiencies, AirJoule® is being commercialized through a joint venture with GE Vernova and through partnerships with Carrier Global Corporation and BASF. For more information, visit www.mt.energy.

About TenX

TenX Investment in Energy Enterprises & Management Co. LLC specializes in investing and bringing the best international energy solutions to the UAE and the broader MENA region. As a Dubai–based SME investment company, we leverage our extensive connections and strategic partnerships to provide unparalleled access to innovative energy technologies and services, ensuring our clients stay ahead in a rapidly evolving industry. Additionally, we invest in cutting–edge technologies to further support sustainable energy advancements, reinforcing our commitment to driving efficiency and sustainability in the energy sector. For more information, visit www.10xinvestment.ae.

Contacts

Montana Technologies
Tom Divine – Vice President, Investor Relations and Finance
investors@mt.energy

TenX
contact@10xinvestment.ae

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cb0cb774–a23c–4b25–befd–4a606372f3d4


GLOBENEWSWIRE (Distribution ID 9205735)

Blue Hat Expands into Gold Trading with Strategic Partnerships As Gold Prices Rise Amid Economic Optimism

HONG KONG, Aug. 15, 2024 (GLOBE NEWSWIRE) — Blue Hat Interactive Entertainment Technology (NASDAQ:BHAT) is emerging as a key player in gold trading industry. As reported by Reuters, since August 1st, 2024, gold prices have exhibited a mix of volatility and upward trends, influenced by various economic and geopolitical factors. Gold hit a notable high above $2,483 per ounce in July, supported by favorable market sentiment and political risks, indicating strong safe–haven demand​ while short–term corrections might occur due to various economic data releases and market dynamics, the medium to long–term outlook for gold remains bullish, driven by continued safe–haven demand and broader economic uncertainties.

Gold is known for its enduring value and role as a hedge against inflation and financial instability, offering potential returns even in unpredictable market conditions. In today’s volatile global economy, gold remains a stable investment option, prized for its scarcity and universal appeal.

Originally an entertainment company, Blue Hat is now focusing on innovations in the commodity trading arena. The company is planning to integrate artificial intelligence to enhance its offerings, including an intelligent gold supply chain and recycling system, as well as a sophisticated gold derivatives trading platform. Unlike traditional gold companies, Blue Hat is not merely a gold trader earning from the buy–sell spread; rather, it will generate revenue from various aspects of the gold supply chain. Additionally, Blue Hat's gold sources are not limited to newly mined gold but also include gold that recycle from market consumers.

In this environment, Blue Hat Interactive Entertainment Technology is emerging as a key player in gold trading due to their recent business cooperation agreement with Sichuan Jinyinghe Industrial Co., Ltd. in Shenzhen, GTC Group LLC in Dubai and its subsidiary, Golden Alpha Strategy Ltd., has been granted Dealers in Precious Metals and Stones Category A Registration by Hong Kong Customs and Excise Department.

In recent years, with changes in international political and economic situations, central banks of various countries have significantly increased their gold reserves, leading to a rapid rise in gold prices. The Company's management believes that the gold industry has transitioned from a period of rapid growth to a period of high–quality development, presenting strategic development opportunities. However, the gold industry in China and other developing markets still faces numerous challenges, such as low levels of scale and concentration, narrow traditional financing channels, poor operational standards, and a lack of credit data. These issues hinder the healthy development of the gold industry. To effectively address these pain points, Blue Hat and Jinyinghe have decided to cooperate in the gold supply chain business.

According to incomplete statistics from industry insiders, Shuibei is known as the 'World's Gem City, which has nearly 7,000 legal entities in the gold and jewelry industry, employs over 70,000 people, and generates revenue exceeding 1 trillion yuan, accounting for over 50% of the domestic gold and jewelry wholesale market.

The Shenzhen Shuibei market is highly relevant in the gold trade for several reasons:

  1. Central Hub for Gold Trading: Shuibei is known as one of China's largest gold trading centers. It serves as a primary hub for the purchase and sale of gold, attracting traders and buyers from across the country and internationally.
  2. Manufacturing and Processing: The market is a significant center for gold processing and manufacturing. Many companies involved in the creation of gold jewelry and other products operate within this area, making it a vital link in the gold supply chain.
  3. Innovation and Design: Shenzhen Shuibei is known for its innovation in jewelry design. It hosts numerous designers and craftsmen who contribute to the creation of new and unique gold jewelry pieces, which helps to set trends in the industry.
  4. Economic Impact: The market plays a crucial role in the local and national economy, generating substantial revenue and employment. Its activities significantly contribute to China's position as a leading player in the global gold market.
  5. Integration with Technology: The market has increasingly integrated technology in its operations, using digital platforms for trading and showcasing products, which enhances its efficiency and reach.

Besides, Blue Hat’s digital trading solutions are designed to provide flexibility, allowing traders to capitalize on gold price movements without the need for physical storage and insurance. These platforms enable traders to navigate the gold market efficiently, benefiting from high liquidity and continuous market activity. This liquidity allows traders to enter and exit positions swiftly, contributing to the fluidity of the gold market.

Looking ahead, Blue Hat aims to expand its global reach and strengthen its position in the gold market. The company plans to increase its gold holdings, enhance supply chain operations, and refine its digital trading platform. These initiatives are part of Blue Hat's strategy to establish itself as a leading “Smart Gold Trading Platform,” targeting markets in Europe, North America, and beyond.

Forward–Looking Statements:

This press release contains forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including, without limitation, statements regarding the Company's ability to regain compliance with Nasdaq listing standards, are forward–looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” “schedule,” and “would” and similar expressions are intended to identify forward–looking statements, although not all forward–looking statements contain these identifying words. These forward–looking statements are predictions based on our current expectations and projections about future events and various assumptions. We cannot guarantee that we will achieve the plans, intentions, or expectations disclosed in our forward–looking statements and you should not place undue reliance on our forward–looking statements. These forward–looking statements involve known and unknown risks, uncertainties, and other factors, which may be beyond our control, and which may cause our actual results, performance, or achievements to differ materially from future results, performance, or achievements expressed or implied by such forward–looking statements.  There are a number of important factors that could cause our actual results to differ materially from those indicated or implied by its forward–looking statements including, without limitation, whether our cash resources will be sufficient to fund continuing operations and allow us to comply with regulatory and stock exchange listing requirements. All forward–looking statements included in this press release are made as of the date hereof and are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in the Company’s Annual Report on Form 10–K, and otherwise in the Company’s subsequent filings and reports filed with Securities and Exchange Commission. The Company does not assume any obligation to update any forward–looking statements and it disclaims any intention or obligation to update or revise any forward–looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.

For more information about Blue Hat, please visit Blue Hat's website.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dad7e01d–9cb3–4e2b–b617–883a53d74e67

Contacts:

Blue Hat Interactive Entertainment Technology

Phone: +86 (592) 228–0010

Email: ir@bluehatgroup.net

IR Website: https://ir.bluehatgroup.com


GLOBENEWSWIRE (Distribution ID 9205663)

Cellebrite Announces Redemption of All Outstanding Warrants

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT) (“Cellebrite,” the “Company” or “we”), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today that it will redeem all of its warrants (the “Warrants”) to purchase ordinary shares of the Company (the “Ordinary Shares”) that remain outstanding at 5:00 p.m. New York City time on September 16, 2024 (the “Redemption Date”) for a redemption price of $0.10 per Warrant.

The Warrants include (i) the outstanding public warrants to purchase Ordinary Shares (the “Public Warrants”) issued pursuant to that certain Assignment, Assumption and Amended and Restated Warrant Agreement, dated on August 30, 2021 (the “Warrant Agreement”), between the Company and Equiniti Trust Company, LLC (as successor to American Stock Transfer & Trust Company, LLC) (“Equiniti”), which were originally issued by TWC Tech Holdings II Corp. (“TWC”) in connection with its initial public offering and subsequently assumed by the Company and converted into warrants to purchase Ordinary Shares of the Company as a result of the Company’s business combination with TWC which was consummated on August 30, 2021 (the “Business Combination”), for a redemption price of $0.10 per Public Warrant (the “Redemption Price”) and (ii) the outstanding private placement warrants to purchase Ordinary Shares (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”) originally issued by TWC in a private placement transaction under the Private Placement Warrants Purchase Agreement, dated as of September 10, 2020, by and between TWC and TWC Tech Holdings II, LLC, and converted into warrants to purchase Ordinary Shares of the Company as a result of the Business Combination, on the same terms as the outstanding Public Warrants.

Equiniti serves as warrant agent (the “Warrant Agent”) with respect to the Warrants.

The Warrant Agreement provides that the Company is entitled to redeem all of the outstanding Public Warrants at the Redemption Price of $0.10 per Public Warrant where: (i) the last reported sales price of the Ordinary Shares for any twenty trading days within the thirty trading–day period ending on the third trading day prior to the date on which notice of the redemption is given (the “Reference Value”) equals or exceeds $10.00 per share, and (ii) if the Reference Value is less than $18.00 per share, the Private Placement Warrants are also concurrently called for redemption on the same terms as the outstanding Public Warrants. The Reference Value currently equals or exceeds $10.00 per share and is less than $18.00 per share, such that the Company is entitled to call the Warrants for redemption. At the direction of the Company, the Warrant Agent has delivered today a notice of redemption (the “Notice of Redemption”) to each of the registered holders of the outstanding Warrants.

At any time after the Notice of Redemption has been delivered and prior to 5:00 p.m. New York City time on the Redemption Date, Warrantholders may elect to: (1) exercise their Warrants for cash, at an exercise price of $11.50 per Ordinary Share, or (2) surrender their Warrants on a “cashless basis” (a “Make–Whole Exercise”), in which case the surrendering holder will receive a number of Ordinary Shares determined in accordance with the terms of the Warrant Agreement and based on the Redemption Date and the volume–weighted average price (the “Redemption Fair Market Value”) of the Ordinary Shares during the ten trading days immediately following the date on which the Notice of Redemption is sent to registered holders of Warrants.

The Company has obtained a ruling (the “Ruling”) from the Israeli Tax Authorities, as further described in the Notice of Redemption, that exempts the Company from the potential obligation to withhold tax upon the issuance of Ordinary Shares to holders (“Qualified Holders”) of the Public Warrants who effect a Make–Whole Exercise and meet the requirements of the Ruling. Warrantholders who exercise for cash and Warrantholders who are not Qualified Holders will be subject to Israeli withholding tax requirements, unless certain requirements described in the Notice of Redemption are satisfied.

The Company expects to provide holders notice of the Redemption Fair Market Value on August 30, 2024. In no event will the number of Ordinary Shares issued in connection with a surrender of Warrants on a cashless basis, as described above, exceed 0.361 Ordinary Shares per Warrant.

Any Warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be void and no longer exercisable, and the holders of those Warrants will be entitled to receive only the Redemption Price, net of any applicable tax withholding, or as otherwise described in the Notice of Redemption.

Ordinary Shares underlying the Warrants and issuable pursuant to a Make–Whole Exercise will be issued in reliance upon the exemption from registration provided by Section 3(a)(9) under the Securities Act of 1933, as amended (the “Securities Act”). Ordinary Shares underlying the Warrants and issued pursuant to an exercise for cash have been registered by the Company under the Securities Act and are covered by a registration statement on Form F–3 filed with, and declared effective by, the Securities and Exchange Commission (Registration No. 333–259826). The SEC maintains an Internet website that contains a copy of the prospectus included in the registration statement at www.sec.gov. Alternatively, you can obtain a copy of this prospectus on the Investor Relations section of the Company’s website, at https://investors.cellebrite.com. 

The Ordinary Shares and the Public Warrants are listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbols “CLBT” and “CLBTW,” respectively. We understand from Nasdaq that September 13, 2024, the trading day prior to the Redemption Date, will be the last day on which the Public Warrants will be traded on Nasdaq.

None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Warrants as to whether to exercise or refrain from exercising any Warrants.

This press release does not and will not constitute an offer to sell, or the solicitation of an offer to buy, the Warrants, the Ordinary Shares, or any other securities, nor will there be any sale of the Warrants, the Ordinary Shares or any such other securities, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

Additional information regarding this announcement may be found in a Form 6–K that will be filed with the U.S. Securities and Exchange Commission.

Any questions you may have about redemption and exercising your Warrants may be directed to the Company’s Information Agent at.

D.F. King & Co., Inc.
48 Wall Street
New York, NY 10005
Banks and Brokerage Firms, Please Call: (212) 269–5550
Stockholders and All Others Call Toll–Free: (800) 431–9643
Email: CLBTW@dfking.com 

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Caution Regarding Forward Looking Statements

This document includes “forward–looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward–looking statements include, but are not limited to, statements related to the Redemption Date, withholding tax and the Redemption Fair Market Value notice. Such forward–looking statements are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward–looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; failure to manage its growth effectively; Cellebrite’s ability to introduce new solutions and add–ons; its dependency on its customers renewing their subscriptions; the low volume of business Cellebrite conducts via e–commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite’s solutions; near term declines in new or renewed agreements; risks associated with inability to retain qualified personnel and senior management; the security of Cellebrite’s operations and the integrity of its software solutions; risks associated with the negative publicity related to Cellebrite’s business and use of its products; risks related to Cellebrite’s intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite’s operations in Israel, including the ongoing Israel–Hamas war and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti–corruption, trade compliance, anti–money–laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20–F filed with the SEC on March 21, 2024 and as amended on April 12, 2024, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward–looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward–looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Media 

Victor Cooper 
Sr. Director of Corporate Communications + Content Operations 
Victor.cooper@cellebrite.com 
+1 404.804.5910 

Investor Relations 

Andrew Kramer 
Vice President, Investor Relations 
investors@cellebrite.com 
+1 973.206.7760


GLOBENEWSWIRE (Distribution ID 9205262)

Cellebrite Appoints Tech Veteran Troy K. Richardson to Board of Directors

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier digital investigative solutions for the public and private sectors, announced today that Troy Richardson has joined its board of directors, effective August 13, 2024.

Mr. Richardson is a seasoned technology executive with more than 30 years of experience in leading, scaling and transforming global organizations. He currently serves on the Unisys Corporation (NYSE: UIS) Board of Directors and previously served as a Director of the Board for Carestream Dental. Mr. Richardson was president of the Digital Thread group at PTC Inc. (NASDAQ: PTC) from 2021 until 2022 after having served as executive vice president and chief operating officer from 2020 to 2021. Mr. Richardson’s three decades of senior leadership roles span some of the largest and most successful global technology companies including DXC (formerly Computer Sciences Corporation prior to its merger with HP Enterprise), Oracle, SAP, Hewlett–Packard Novell, and IBM. With the appointment of Troy Richardson, Cellebrite’s Board of Directors now consists of 10 directors. Mr. Richardson is based in metropolitan Atlanta.

“We are delighted to welcome Troy to our board of directors,” said Thomas Hogan, Executive Chairman of the Board of Cellebrite. “Troy is an outstanding leader who brings a wealth of expertise and insight to our Company. His deep knowledge of the software industry, combined with his broad leadership experience spanning sales, marketing, corporate development and customer success, will be invaluable as we continue to execute our strategy and deliver outstanding value to our customers. We look forward to benefiting from Troy’s counsel as we further scale our business, fortify and expand our market leadership, advance innovation and drive shareholder value.”

“I am honored and excited to join Cellebrite's board of directors,” said Richardson. “Cellebrite has established its leadership position in the digital investigative and intelligence gathering industry, with a strong culture of innovation, customer focus, and social responsibility. I look forward to collaborating with Tom and the rest of the Board, as well as with Cellebrite’s talented management team and employees, to help Cellebrite achieve its full potential and continue making a positive, enduring impact on the world.”

Mr. Richardson holds a bachelor's degree in business administration from Eastern Illinois University and a master's degree in business administration from Northwestern University’s J.L. Kellogg School of Management. He was appointed to Unisys’ Corporation’s Board of Directors in 2021 and currently serves on the Board’s Audit & Finance and Rick & Security Committees. Mr. Richardson also served on Carestream Dental Board of Directors from 2021 to 2024.

About Cellebrite

Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.

Contacts:

Media
Victor Ryan Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investors
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/947dd533–8273–47a0–9fdb–eac0d18d28c5


GLOBENEWSWIRE (Distribution ID 9204183)

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.

“We continue to deliver strong execution with key milestones achieved during the second quarter of 2024 across each of our N–Tab™ oral peptide programs dedicated to patients with OBGYN/endocrinology, GI and metabolic diseases,” said Miranda Toledano, Entera’s CEO. “Importantly, we are now just five months away from FDA’s potential landmark ruling on the ASBMR–FNIH SABRE regulatory endpoint for osteoporosis drugs, which we view as a major catalyst for EB613. We are especially keen to start our pivotal study of EB613 in a much wider population where injectable anabolic drugs do not play a dominant role. Because of its potential dual mechanism of action, faster onset of action as an anabolic boosting agent and oral minitablet format, we believe EB613 is uniquely positioned to support earlier osteoanabolic intervention in post–menopausal women at high risk of fracture,” she added.

EB613: First Oral PTH(1–34) Daily Osteoanabolic Tablets for Osteoporosis

  • In April 2024, the Journal of Bone and Mineral Research (JBMR) published “Oral daily PTH(1–34) Tablets [EB613] in Postmenopausal Women with Low BMD or Osteoporosis: A Randomized, Placebo–Controlled, 6–Month, Phase 2 Study”
  • In May 2024, Entera welcomed Dr. Rachel Wagman as Key Clinical Advisor to lead EB613 clinical development. Wagman has successfully advanced the development of five molecules, including the osteoporosis products Forteo®, Prolia® and Evenity® through registration
  • In June 2024, the JMBR published an independent editorial titled “A Novel Oral hPTH(1–34) [EB613] Unveils the Promise of Modeling–Based Anabolism with No Increase in Bone Remodeling”
  • In July 2024, Entera announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the ASBMR September 2024 Annual Meeting in Toronto
  • In July 2024, Entera announced that the SABRE (Study to Advance BMD as a Regulatory Endpoint) is expected to provide an update at the ASBMR September 2024 Annual Meeting in Toronto

EB612: First Oral PTH(1–34) Peptide Replacement Therapy Tablets for Hypoparathyroidism

  • In June 2024, Entera presented Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, at the Endocrine Society ENDO 2024 Annual Meeting. Entera showed that the data supports potentially moving the BID (twice–daily) tablet dose to Phase 2 development in patients with hypoparathyroidism
  • Entera continues to collaborate with a third party on the development of another PTH replacement treatment for hypoparathyroidism

First GLP–2 Peptide Tablets for Short Bowel Syndrome

  • In March 2024, Entera announced positive in vivo PK results from its program combining OPKO Health, Inc.’s (Nasdaq: OPK) long acting GLP–2 analogue with N–Tab™ technology. Pharmacology data is expected early in the second half of 2024

First GLP–1/Glucagon Agonist (Oxyntomodulin) Peptide Tablets for Obesity

  • Collaborative work is ongoing combining N–Tab™ with OPKO’s long–acting Oxyntomodulin (OXM) analogues for potential treatment for obesity and other metabolic diseases. PK data for the oral OXM tablet are expected early in the second half of 2024

Financial Results for the Quarter Ended June 30, 2024

As of June 30,2024, Entera had cash and cash equivalents of $9.1 million. The Company expects that its existing cash resources are sufficient to meet its projected operating requirements into the third quarter of 2025.

Research and development expenses for the three months ended June 30, 2024 were $1.1 million, as compared to $1.2 million for the three months ended June 30, 2023. The decrease of $0.1 million was primarily due to a decrease of $0.3 million in clinical expenses for our Phase 1 PK study related to our new generation platform and new formulations for EB612, which completed its first stage in 2023.

General and administrative expenses for both the three months ended June 30, 2024 and 2023 were $1.1 million.

Operating expenses for the period ended June 30, 2024 were $2.2 million, as compared to $2.3 million for the quarter ended June 30, 2023.

Net loss was $2.1 million, or $0.06 per ordinary share (basic and diluted), for the quarter ended June 30, 2024, as compared to $2.3 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended June 30, 2023.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline includes five differentiated, first–in–class oral peptide programs, expected to enter the clinic (Phase 1 to Phase 3) by 2025. The Company’s most advanced product candidate, EB613 (oral PTH (1–34)), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis, with no prior fracture. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint which is expected to occur by January 2025. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s expectations regarding licensing, business transactions and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statements Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as the company’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

ENTERA BIO LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
 
  June 30,   December 31,
  2024   2023
  (Unaudited)   (Audited)
   
Cash and cash equivalents 9,056   11,019
Accounts receivable and other current assets 539   238
Property and equipment, net 76   100
Other assets, net 364   408
Total assets 10,035   11,765
       
       
Accounts payable and other current liabilities 1,294   1,091
Total non–current liabilities 219   288
Total liabilities 1,503   1,379
Total shareholders' equity 8,532   10,386
       
Total liabilities and shareholders' equity 10,035   11,765
 

ENTERA BIO LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
(Unaudited)
 
  Three Months Ended
June 30,
  2024   2023  
REVENUES 57   –  
COST OF REVENUES 48   –  
GROSS PROFIT 9   –  
OPERATING EXPENSES:    
Research and development 1,086   1,209  
General and administrative 1,088   1,135  
Other income –   (14)  
TOTAL OPERATING EXPENSES 2,174   2,330  
OPERATING LOSS 2,165   2,330  
FINANCIAL INCOME, NET (20)   (5)  
NET LOSS 2,145   2,325  
     
LOSS PER SHARE BASIC AND DILUTED 0.06   0.08  
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING         
USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE 37,090,160   28,812,375  
     


GLOBENEWSWIRE (Distribution ID 9202470)

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

  • Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading technology–first, end–to–end drug discovery platform
  • Combined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methods
  • Highly complementary pipeline with approximately 10 clinical readouts expected over the next 18 months
  • Industry–leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion overall before potential royalties over the course of the partnership
  • Well–capitalized balance sheet with approximately $850 million in cash and cash equivalents between the two companies as of the end of Q2 2024
  • Operational complementarities expected to yield annual synergies in excess of $100 million

SALT LAKE CITY and OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) today announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology–enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology–driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster.

“We believe the proposed combination is deeply complementary and aligned with our missions to industrialize drug discovery to deliver high quality medicines and lower prices for consumers,” said Chris Gibson, Ph.D., Co–Founder and CEO of Recursion as well as the planned CEO of the combined entity. “Exscientia’s precision chemistry tools and capabilities, including its newly commissioned automated small molecule synthesis platform, will augment our tech–enabled biology and chemistry exploration, hit discovery and translational capabilities. I am excited to continue building the best example of the next generation of biotechnology companies. It still feels like we are just getting started.”

“Adding Exscientia’s best–in–class focused precision oncology internal pipeline to Recursion’s first–in–class focused pipeline spanning rare disease, precision oncology and infectious disease is highly complementary as we look to bring treatments to patients faster,” said David Hallett, Ph.D., Interim Chief Executive Officer and planned Chief Scientific Officer of Recursion post–closing of the transaction. “We look forward to bringing our teams together and integrating Recursion's high throughput and target biology capabilities with Exscientia's highly scalable molecular design and automated chemistry synthesis capabilities to truly accelerate the discovery of better drugs for patients.”

Once integrated, the companies believe the extended and evolved Recursion OS will enable the discovery and translation of higher quality medicines more efficiently and at a higher scale with a full–stack technology–enabled small molecule discovery platform. In addition, the combined company expects to read out approximately 10 clinical trials in the next 18 months.

The proposed business combination will also advance significant therapeutic discovery collaborations with some of the most prominent biopharma companies in the world, including Roche–Genentech, Sanofi, Bayer, and Merck KGaA. Moreover, there is the potential for approximately $200 million in milestone payments over the next 2 years from these current partnerships and there is the potential for more than $20 billion in revenue before royalties on net–sales of partnership programs which range from mid single–digit to double–digit royalties over the course of the partnership.

Strategic Rationale

  • Pipeline: The combination would create a diverse portfolio of clinical and near–clinical programs (approximately 10 clinical readouts expected in the next 18 months) where most of these programs, if successful, could have annual peak sales opportunities in excess of $1 billion. In addition to Recursion’s internal pipeline, Exscientia has wholly–owned oncology programs associated with targets CDK7 (clinical), LSD1, and MALT1 as well as partnered programs associated with targets PKC–Theta (clinical) and ENPP1. Across the combined pipeline there is no competitive overlap, with Recursion’s pipeline focusing on first–in–class drug candidates within oncology, rare disease, and infectious disease and Exscientia’s focus on best–in–class drug candidates within oncology. Additionally, for both companies there are many research and discovery stage pipeline programs that would benefit from the complementary combination of the two platforms.
  • Partnerships: The proposed business combination would bring together transformational partnerships with leading large pharma companies with a total of 10 programs already optioned across oncology and immunology. In addition to Recursion’s transformational partnerships with Roche–Genentech (neuroscience and a gastrointestinal oncology indication) and Bayer (undruggable oncology), Exscientia has partnerships with Sanofi (immunology and oncology) and Merck KGaA (oncology and immunology). In addition, Exscientia has a partnership with BMS (oncology and immunology) where an optioned program related to PKC–Theta has already shown positive early Phase 1 results. Furthermore, the combined company expects potential additional milestone payments of approximately $200 million over the next 2 years from its current partnerships.
  • Platform: The combination will help enable a full–stack technology–enabled platform spanning patient–centric target discovery, structure based drug design including hotspot analysis, quantum mechanics and molecular dynamics modeling, 2D and 3D generative AI design, encode and automate design–make–test–learn cycles with active learning, automated chemical synthesis, predictive ADMET and translation, biomarker selection, clinical development, and more. Furthermore, Exscientia’s automated chemistry design and synthesis capabilities are expected to allow Recursion to more rapidly and effectively run SAR cycles during hit to lead and lead optimization. These capabilities are expected to generate diverse chemistry to experimentally improve our predictive maps of biology and chemistry.

Transaction Details
Under the terms of the transaction agreement, which were unanimously approved by the boards of directors of both companies, Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share they own, with fractional shares paid in cash. Based on the fixed exchange ratio, Recursion shareholders will own approximately 74% and Exscientia shareholders will own approximately 26% of the combined company, in each case assuming no additional issuance by either company before closing. Major shareholders of each company, including holders of more than 40% of Exscientia shares, have entered into agreements on customary terms and conditions under which they have agreed to vote all their shares in favor of the transaction. There is approximately $850 million in cash and cash equivalents held by both companies at the end of Q2 2024. The combined company is estimated to achieve annual synergies of approximately $100 million with a runway extending into 2027.

The combination is expected to be implemented through a court sanctioned scheme of arrangement under English law and is subject to the satisfaction of customary closing conditions, including the approval of Exscientia shareholders, the approval of Recursion’s stockholders, and the sanction of the High Court of Justice of England and Wales, and the receipt of required regulatory approvals. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by early 2025.

Listing, Governance and Management
The combined company, which will be named Recursion, will continue to be headquartered in Salt Lake City, Utah, and trade on the NASDAQ, while maintaining a significant presence in the U.K. Chris Gibson, Ph.D., Co–Founder & CEO of Recursion, will serve as CEO of the combined company and David Hallett, Ph.D., Interim Chief Executive Officer & Chief Scientific Officer of Exscientia, plans to join the combined company as Chief Scientific Officer. Two existing Exscientia directors will join the Board of Recursion following the closing of the transaction.

Advisors
Allen & Company LLC acted as exclusive financial advisor to Recursion and Wilson Sonsini Goodrich & Rosati acted as legal counsel. Centerview Partners LLC acted as exclusive financial advisor to Exscientia and A&O Shearman acted as legal counsel.

About Recursion
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient–centric datasets. Recursion leverages sophisticated machine–learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale—up to millions of wet lab experiments weekly—and massive computational scale—owning and operating one of the most powerful supercomputers in the world—Recursion is uniting technology, biology, chemistry and patient–centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area and London.

About Exscientia
Exscientia is a technology–driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI–designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.

Recursion Investor Relations
investor@recursion.com

Recursion Media
media@recursion.com

Exscientia Investor Relations
investors@exscientia.ai

Exscientia Media
media@exscientia.ai

Forward Looking Statements
Statements contained herein which are not historical facts may be considered forward–looking statements under federal securities laws and may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the proposed business combination of Recursion and Exscientia and the outlook for Recursion’s or Exscientia’s future business and financial performance such as delivering better treatments to patients, faster and at a lower cost; the discovery and translation of higher quality medicines more efficiently and at a higher scale; helping to enable a full–stack technology–enabled platform; allowing Recursion to more rapidly and effectively run SAR cycles during hit to lead optimization; generating the diverse chemistry to experimentally improve predictive maps; the number and timing of clinical program readouts over the next 18 months; the combined company’s first–in–class and best–in–class opportunities; potential for sales from successful programs with annual peak sales opportunities of over $1 billion each; potential for approximately $200 million in milestone payments over the next 24 months, and over $20 billion in revenue before royalties over the course of the partnerships; percentage of the combined company to be received by Exscientia shareholders; cash runway extending into 2027; the value of estimated annual synergies; implementing the combination through a UK scheme of arrangement; the expected closing of the transaction by early 2025; continuing to build the best example of the next generation of biotechnology companies; the plans for David Hallett, Ph.D. to join the combined company as Chief Scientific Officer; and many others. Such forward–looking statements are based on the current beliefs of Recursion’s and Exscientia’s respective management as well as assumptions made by and information currently available to them, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may vary materially from these forward–looking statements based on a variety of risks and uncertainties including: the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; the inability to obtain Recursion’s  stockholder approval or Exscientia’s shareholder approval or the failure to satisfy other conditions to completion of the proposed combination, including obtaining the sanction of the High Court of Justice of England and Wales to the Scheme of Arrangement, on a timely basis or at all, and the receipt of required regulatory approvals; risks that the proposed combination disrupts each company’s current plans and operations; the diversion of the attention of the respective management teams of Recursion and Exscientia from their respective ongoing business operations; the ability of either Recursion, Exscientia  or the combined company to retain key personnel; the ability to realize the benefits of the proposed combination, including cost synergies; the ability to successfully integrate Exscientia's business with Recursion’s business, at all or in a timely manner; the outcome of any legal proceedings that may be instituted against Recursion, Exscientia or others following announcement of the proposed combination; the amount of the costs, fees, expenses and charges related to the proposed combination; the effect of economic, market or business conditions, including competition, regulatory approvals and commercializing drug candidates, or changes in such conditions, have on Recursion’s, Exscientia’s and the combined company’s operations, revenue, cash flow, operating expenses, employee hiring and retention, relationships with business partners, the development or launch  of technology enabled drug discovery, and commercializing drug candidates; the risks of conducting Recursion’s and Exscientia’s business internationally; the impact of changes in interest rates by the Federal Reserve and other central banks; the impact of potential inflation, volatility in foreign currency exchange rates and supply chain disruptions; the ability to maintain technology–enabled drug discovery in the biopharma industry; and risks relating to the market value of Recursion’s common stock to be issued in the proposed combination.

Other important factors and information are contained in Recursion’s most recent Annual Report on Form 10–K and Exscientia’s most recent Annual Report on Form 20–F, including the risks summarized in the section entitled “Risk Factors,” Recursion’s most recent Quarterly Reports on Form 10–Q and Exscientia’s filing on Form 6–K filed May 21, 2024, and each company’s other periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed at https://ir.recursion.com in the case of Recursion, http://investors.exscientia.ai in the case of Exscientia, or www.sec.gov. All forward–looking statements are qualified by these cautionary statements and apply only as of the date they are made. Neither Recursion nor Exscientia undertakes any obligation to update any forward–looking statement, whether as a result of new information, future events or otherwise.

Additional Information and Where to Find It
This communication relates to a proposed business combination of Recursion and Exscientia that will become the subject of a joint proxy statement to be filed by Recursion with the SEC. The joint proxy statement will provide full details of the proposed combination and the attendant benefits and risks, including the terms and conditions of the scheme of arrangement and the other information required to be provided to Exscientia's shareholders under the applicable provisions of the U.K. Companies Act 2006. This communication is not a substitute for the joint proxy statement or any other document that Recursion or Exscientia may file with the SEC or send to their respective stockholders in connection with the proposed combination. Investors and security holders are urged to read the definitive joint proxy statement and all other relevant documents filed with the SEC or sent to Recursion’s stockholders or Exscientia’s shareholders as they become available because they will contain important information about the proposed combination. All documents, when filed, will be available free of charge at the SEC’s website (www.sec.gov). You may also obtain these documents by contacting Recursion’s Investor Relations department at investor@recursion.com; or by contacting Exscientia’s Investor Relations department at investors@exscientia.ai. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.

Participants in the Solicitation
Recursion, Exscientia and their respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed business combination. Information about Recursion’s directors and executive officers is available in Recursion’s proxy statement dated April 23, 2024 for its 2024 Annual Meeting of Stockholders. Information about Exscientia’s directors and executive officers is available in Exscientia’s proxy statement dated March 21, 2024 for its 2024 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement and all other relevant materials to be filed with the SEC regarding the proposed combination when they become available. Investors should read the joint proxy statement carefully when it becomes available before making any voting or investment decisions.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83e2ee85–7b58–4008–b558–a17965edff48


GLOBENEWSWIRE (Distribution ID 9201657)

Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results
FDA regulatory submission complete, U.S. approval on track for end of 2024
U.S. commercial launch fully funded with over €85 million in new capital raised

Mont–Saint–Guibert, Belgium – August 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2024.  

Recent Financial and Operating Highlights

  •  Submitted final module in the modular PMA submission, initiating FDA interactive review.
  •  Strengthening U.S. commercial organization, highlighted by the appointments of Scott Holstine as Chief Commercial Officer and key sales, marketing and market access leaders.
  •  Raised over €85 million in growth capital through a €48.5 million equity offering and a €37.5 million loan facility agreement with the European Investment Bank (EIB).
  •  Reported second quarter 2024 sales of €0.8 million and first half 2024 sales growth of 29% over the same period last year.
  •  Total cash position of €77.8 million at the end of the quarter, excluding the €37.5 million EIB loan facility.

“With the FDA interactive review well advancing, our focus is fully shifted to U.S. commercial readiness. Key commercial leadership is in place, and we are kicking off the recruitment of top sales and marketing talents. We will present the full DREAM U.S. pivotal study data at the ISSS meeting in September, which will further differentiate Genio’s unique, patient centric hypoglossal nerve stimulation solution,” commented Olivier Taelman, Nyxoah Chief Executive officer. “Our recent €85 million in capital raise provides us with a cash runway into mid–2026, fully funding the U.S. launch.”

Second Quarter and First Half 2024 Results

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)
 (in thousands)

  For the three months ended June 30,    For the six months ended June 30, 
  2024   2023   2024   2023
Revenue  771   1,107   1,992   1,548
Cost of goods sold  (281)   (419)   (735)   (594)
Gross profit  €490   €688   €1,257   €954
Research and Development Expense  (7,472)   (6,605)   (14,671)   (12,762)
Selling, General and Administrative Expense  (6,383)   (6,185)   (12,355)   (11,736)
Other income/(expense)  58   219   249   265
Operating loss for the period  €(13,307)   €(11,883)   €(25,520)   €(23,279)
Financial income  2,069   789   3,477   1,414
Financial expense  (1,445)   ( 775)   (2,436)   (1,732)
Loss for the period before taxes  €(12,683)   €(11,869)   €(24,479)   €(23,597)
Income taxes  (441)   (928)   (551)   (1,110)
Loss for the period  €(13,124)   €(12,797)   €(25,030)   €(24,707)
               
Loss attributable to equity holders  € (13,124)   €(12,797)   €(25,030)   €(24,707)
               
Other comprehensive income/(loss)               
Items that may not be subsequently reclassified to profit or loss (net of tax)               
Currency translation differences  (82)   (50)   (22)   (78)
Total comprehensive loss for the year, net of tax  €(13,206)   €(12,847)   €(25,052)   €(24,785)
Loss attributable to equity holders  €(13,206)   €(12,847)   €(25,052)   €(24,785)
               
Basic loss per share (in EUR)  €(0.428)   €(0.447)   €(0.843)   €(0.907)
Diluted loss per share (in EUR)  €(0.428)   €(0.447)   €(0.843)   €(0.907)

 CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited)
(in thousands)

      As at 
      June 30,
2024 		  December 31, 2023
ASSETS          
Non–current assets          
Property, plant and equipment     4,386   4,188
Intangible assets     49,310   46,608
Right of use assets     3,391   3,788
Deferred tax asset     51   56
Other long–term receivables     1,419   1,166
      € 58,557   € 55,806
Current assets          
Inventory     5,098   3,315
Trade receivables     2,609   2,758
Other receivables     2,885   3,212
Other current assets     1,298   1,318
Financial assets     50,061   36,138
Cash and cash equivalents     27,724   21,610
      € 89,675   € 68,351
Total assets     € 148,232   € 124,157
           
EQUITY AND LIABILITIES          
Capital and reserves          
Capital     5,905   4,926
Share premium     290,822   246,127
Share based payment reserve     8,841   7,661
Other comprehensive income     115   137
Retained loss     (185,540)   (160,829)
Total equity attributable to shareholders     € 120,143   € 98,022
           
LIABILITIES          
Non–current liabilities          
Financial debt     8,600   8,373
Lease liability     2,721   3,116
Pension liability     35   9
Provisions     339   185
Deferred tax liability     10   9
      €11,705   € 11,692
Current liabilities          
Financial debt     595   364
Lease liability     827   851
Trade payables     9,078   8,108
Current tax liability     2,335   1,988
Other payables     3,549   3,132
      € 16,384   € 14,443
Total liabilities     € 28,089   € 26,135
Total equity and liabilities     € 148,232   € 124,157

Revenue
Revenue was €0.8 million for the second quarter ending June 30, 2024, compared to €1.1 million for the second quarter ending June 30, 2023. 

Cost of Goods Sold

Cost of goods sold was €281,000 for the three months ending June 30, 2024, representing a gross profit of €490,000, or gross margin of 63.6%. This compares to total cost of goods sold of €419,000 in the second quarter of 2023, for a gross profit of €0.7 million, or gross margin of 62.2%. 

Research and Development
For the second quarter ending June 30, 2024, research and development expenses were €7.5 million, versus €6.6 million for the second quarter ending June 30, 2023.

Operating Loss
Total operating loss for the second quarter ending June 30, 2024 was €13.3 million versus €11.9 million in the second quarter ending June 30, 2023. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities. 

Cash Position
As of June 30, 2024, cash and financial assets totaled €77.8 million, compared to €57.7 million on December 31, 2023. Total cash burn was approximately €4.0 million per month during the second quarter 2024.

Second Quarter and First Half 2024
Nyxoah’s financial report for the second quarter and first half 2024, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation 
Company management will host a conference call to discuss financial results on Tuesday, August 6, 2024, beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link:Nyxoah's Q2 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q2 2024 earnings call. After registering, an email will be sent, including dial–in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call. 

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please see the Company’s annual report for the financial year 2023 and visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the entry into of the loan facility agreement and the synthetic warrant agreement with the EIB; the use of proceeds from the loan facility agreement; the Genio® system and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; reporting data from Nyxoah’s DREAM U.S. pivotal trial; filing for FDA approval; and entrance to the U.S. market. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

For Media
Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/Germany
MC Services – Anne Hennecke
anne.hennecke@mc–services.eu

Attachment


GLOBENEWSWIRE (Distribution ID 1000985126)

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024

INFORMATIONS RÉGLEMENTÉES

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Deuxième Trimestre et Premier Semestre 2024
Soumission réglementaire auprès de la complétée, l'approbation aux États–Unis est en bonne voie pour la fin de 2024
Le lancement commercial aux États–Unis est entièrement financé avec plus de 85 millions d'euros de nouveaux capitaux levés

Mont–Saint–Guibert, Belgique – 6 Août 2024, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). Elle annonce aujourd’hui ses résultats financiers et d’exploitation pour le deuxième trimestre et le premier semestre 2024.

Temps forts financiers et d’exploitation

  •  Soumission du dernier module de la demande modulaire d'autorisation de mise sur le marché (PMA), initiant l'examen interactif de la FDA.
  •  Renforcement de l'organisation commerciale aux États–Unis, avec notamment la nomination de Scott Holstine au poste de Chief Commercial Officer et des principaux responsables des ventes, du marketing et de l'accès au marché.
  •  Levée de plus de 85 millions d'euros de capital par le biais d'une offre d'actions de 48,5 millions d'euros et d'un accord de facilité de prêt de 37,5 millions d'euros avec la Banque européenne d'investissement (BEI).
  •  Chiffre d'affaires du deuxième trimestre 2024 de 0,8 million d'euros et croissance du chiffre d'affaires du premier semestre 2024 de 29 % par rapport à la même période de l'année précédente.
  •  Trésorerie totale de 77,8 millions d'euros à la fin du trimestre, à l'exclusion de la facilité de prêt de 37,5 millions d'euros de la BEI.

“L'examen interactif de la FDA étant bien avancé, nous nous concentrons désormais sur la préparation commerciale aux États–Unis. Les principaux responsables commerciaux sont en place et nous commençons à recruter les meilleurs talents dans les domaines de la vente et du marketing. Nous présenterons les données complètes de l'étude U.S. pivot DREAM lors congrès de l'ISSS en septembre, ce qui permettra de mieux différencier la solution de stimulation du nerf hypoglosse de Genio, unique et centrée sur le patient”, a commenté Olivier Taelman, Chief Executive Officer de Nyxoah. “Notre récente levée de fonds de 85 millions d'euros nous permet de disposer de liquidités jusqu'au milieu de l'année 2026 et de financer entièrement le lancement aux États–Unis.”

Résultats du Deuxième Trimestre et Premier Semestre 2024

ÉTATS CONSOLIDÉS DES PERTES ET DES AUTRES PERTES COMPRÉHENSIVES 
(non audités) (en milliers)

  Pour la période de 3 mois terminée le 30 juin    Pour la période de 6 mois terminée le 30 juin
  2024   2023   2024   2023
Chiffre d'affaires 771   1,107   1,992   1,548
Coût des biens vendus (281)   (419)   (735)   (594)
Bénéfice brut €490   €688   €1,257   €954
Frais de recherche et de développement (7,472)   (6,605)   (14,671)   (12,762)
Frais de vente, dépenses administratives et autres frais généraux (6,383)   (6,185)   (12,355)   (11,736)
Autres revenus / (frais) d'exploitation 58   219   249   265
Perte d'exploitation de la période €(13,307)   €(11,883)   €(25,520)   €(23,279)
Produits financiers 2,069   789   3,477   1,414
Charges financières (1,445)   ( 775)   (2,436)   (1,732)
Perte de la période avant impôts €(12,683)   €(11,869)   €(24,479)   €(23,597)
Impôts sur le revenu (441)   (928)   (551)   (1,110)
Perte de la période €(13,124)   €(12,797)   €(25,030)   €(24,707)
               
Perte attribuable aux actionnaires € (13,124)   €(12,797)   €(25,030)   €(24,707)
               
Autres éléments du résultat global              
Éléments qui ne peuvent pas être reclassés ultérieurement en profit ou perte (nets d'impôts)              
Réévaluation des obligations au titre des avantages postérieurs à l’emploi, déduction faite de l’impôt (82)   (50)   (22)   (78)
Éléments susceptibles d’être reclassés ultérieurement en résultat net d’impôt €(13,206)   €(12,847)   €(25,052)   €(24,785)
Différences de conversion des devises €(13,206)   €(12,847)   €(25,052)   €(24,785)
Total des autres éléments du résultat global              
Total du résultat global de l’exercice, déduction faite de l’impôt €(0.428)   €(0.447)   €(0.843)   €(0.907)
Perte attribuable aux actionnaires €(0.428)   €(0.447)   €(0.843)   €(0.907)

ÉTAT DE LA SITUATION FINANCIÈRE CONSOLIDÉ (non audité) (en milliers)

      Au 
      30 juin
2024 		  31 décembre 2023
ACTIFS          
Actifs non courants          
Immobilisations corporelles     4,386   4,188
Immobilisations incorporelles     49,310   46,608
Droit d'utilisation d'actifs     3,391   3,788
Actif d'impôts différés     51   56
Autres créances à long terme     1,419   1,166
      € 58,557   € 55,806
Actifs courants          
Stocks     5,098   3,315
Créances commerciales     2,609   2,758
Autres créances     2,885   3,212
Autres actifs courants     1,298   1,318
Actifs financiers     50,061   36,138
Trésorerie et équivalents de trésorerie     27,724   21,610
      € 89,675   € 68,351
Total de l'actif     € 148,232   € 124,157
           
CAPITAUX PROPRES ET PASSIFS          
Capital et réserves          
Capital     5,905   4,926
Prime d'émission     290,822   246,127
Réserve pour paiement fondés sur des actions     8,841   7,661
Autres éléments du résultat global     115   137
Résultats reportés     (185,540)   (160,829)
Total des capitaux propres attribuables aux actionnaires     € 120,143   € 98,022
           
PASSIFS          
Passifs non courants          
Dettes financières     8,600   8,373
Passifs locatifs     2,721   3,116
Passifs au titre des retraites     35   9
Provisions     339   185
Passif d'impôts différés     10   9
      €11,705   € 11,692
Passifs courants          
Dettes financières     595   364
Passifs locatifs     827   851
Dettes commerciales     9,078   8,108
Passif d'impôts exigibles     2,335   1,988
Autres dettes     3,549   3,132
      € 16,384   € 14,443
Total du passif     € 28,089   € 26,135
Total des capitaux propres et du passif     € 148,232   € 124,157

Revenus
Le chiffre d'affaires s'est élevé à 0,8 million d'euros pour le deuxième trimestre se terminant le 30 juin 2024, contre 1,1 million d'euros pour le deuxième trimestre se terminant le 30 juin 2023. 

Coût des marchandises vendues
Le coût des marchandises vendues s'est élevé à 281 000 € pour le trimestre se terminant le 30 juin 2024, soit une marge brute de 490 000 €, ou une marge brute de 63,6 %. À titre de comparaison, le coût total des marchandises vendues était de 419 000 € au deuxième trimestre 2023, pour un bénéfice brut de 0,7 million €, soit une marge brute de 62,2 %. 

Recherche et développement
Pour le deuxième trimestre clos le 30 juin 2024, les dépenses de recherche et développement se sont élevées à 7,5 millions d'euros, contre 6,6 millions d'euros pour le deuxième trimestre clos le 30 juin 2023.

Perte d'exploitation
La perte d'exploitation totale pour le deuxième trimestre se terminant le 30 juin 2024 s'est élevée à 13,3 millions d'euros, contre 11,9 millions d'euros pour le deuxième trimestre se terminant le 30 juin 2023. Cette évolution s'explique par l'accélération des dépenses de R&D de la Société, ainsi que par les activités commerciales et cliniques en cours.

Position de trésorerie
Au 30 juin 2024, la trésorerie et les actifs financiers s'élevaient à 77,8 millions d'euros, contre 57,7 millions d'euros au 31 décembre 2023.  La consommation totale de trésorerie a été d'environ 4,0 millions d'euros par mois au cours du deuxième trimestre 2024.

Deuxième trimestre et premier semestre 2024

Le rapport financier de Nyxoah pour le deuxième trimestre et le premier semestre 2024, y compris les détails des résultats consolidés audités, sont disponibles sur la page investisseurs du site web de Nyxoah (https://investors.nyxoah.com/financials).

Conférence téléphonique et webcast 

Le management de la Société organisera une conférence téléphonique pour discuter ses résultats financiers le 6 août 2024, à 22h30 CET / 16h30 ET.

La retransmission de la conférence téléphonique sera accessible sur la page Investor Relations du site web de Nyxoah ou par le biais de ce lien : Nyxoah's Q2 2024 earnings call webcast. Pour ceux qui n'ont pas l'intention de poser une question au Management, la Société recommande d'écouter la webdiffusion.

Si vous avez l'intention de poser une question, veuillez utiliser le lien suivant : Nyxoah’s Q2 2024 earnings call. Après l'inscription, un courriel sera envoyé, comprenant les détails de la connexion et un code d'accès unique à la conférence téléphonique nécessaire pour rejoindre l'appel en direct. Pour s'assurer que vous êtes connecté avant le début de la conférence, la Société suggère de s'inscrire au moins 10 minutes avant le début de l'appel.

Le webcast archivé pourra être réécouté peu après la clôture de la conférence.

À propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie. 

Pour plus d’informations, visitez http://www.nyxoah.com/

Attention – Marquage CE depuis 2019. Dispositif expérimental aux États–Unis. Limité par la loi fédérale américaine à une utilisation expérimentale aux États–Unis.

Déclarations Prospectives

Certaines déclarations, croyances et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la société ou, le cas échéant, des administrateurs ou de la direction de la société concernant le système Genio®, les études cliniques prévues et en cours sur le système Genio®, les avantages potentiels du système Genio® ; les objectifs de Nyxoah en ce qui concerne le développement, la voie réglementaire et l'utilisation potentielle du système Genio® ; l'utilité des données cliniques pour l'obtention éventuelle de l'approbation du système Genio® par la FDA ; et les résultats d'exploitation, la situation financière, les liquidités, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prévisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent matériellement de ceux exprimés ou sous–entendus dans les déclarations prévisionnelles. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence négative sur les résultats et les effets financiers des plans et des événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section ” Facteurs de risque ” du rapport annuel de la société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2023, déposé auprès de la Securities and Exchange Commission (” SEC “) le 20 mars 2024, et des rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent de manière significative de tout développement anticipé. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une déclaration selon laquelle ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements peuvent ne pas être représentatifs des résultats ou développements des périodes futures. Aucune déclaration ou garantie n'est donnée quant à l'exactitude ou à la sincérité de ces déclarations prospectives. En conséquence, la société décline expressément toute obligation ou tout engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement des attentes ou d'un changement des événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont basées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces énoncés prospectifs sont exemptes d'erreurs et n'acceptent aucune responsabilité quant à l'exactitude future des énoncés prospectifs contenus dans le présent communiqué de presse ou à la survenance réelle des développements prévus. Vous ne devriez pas accorder une confiance excessive aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :


Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com

Media
Belgique / France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

International/ Allemagne
MC Services – Anne Hennecke
anne.hennecke@mc–services.eu

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1000985126)

DigiAsia Corp. and Jalin, Indonesia’s Largest ATM Network Servicer, Announce Strategic Collaboration

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — DigiAsia Corp. (NASDAQ: FAAS) (“DigiAsia” or the “Company”), a leading Fintech as a Service (“FaaS”) ecosystem provider, and PT Jalin Pembayaran Nusantara (“Jalin”), a subsidiary of the state–owned enterprise holding company Danareksa and a leading digital payment transaction processing company in Indonesia, today announced a strategic collaboration that will advance the penetration of financial inclusion to the underserved across Indonesia. As partners, Jalin’s extensive network of over 52,000 ATMs will be leveraged in coordination with DigiAsia’s Embedded Fintech as a Service Platform delivering innovative financial solutions.

The following core components of the DigiAsia and Jalin partnership prioritize banking the underbanked and underserved and fostering financial inclusion:

  • Cardless Cash Withdrawal (CCW): DigiAsia’s embedded finance application enables users cardless cash withdrawal from Jalin’s vast ATM network, providing greater accessibility and convenience.
  • Cash Deposit Machine (CDM): Expanding the availability of CDMs to facilitate easier cash deposits, supporting individuals and businesses in managing their finances efficiently.
  • White label ATM: DigiAsia’s white label FaaS capabilities offer brand customizable ATM solutions through Jalin’s ATM network to enhance brand presence and service delivery for financial institutions and other partners.
  • Merchant Kiosk: DigiAsia’s 1 million merchants will be deployed Jalin’s merchant kiosks to provide a range of financial services, including payments, transfers, and other transactions, in a user–friendly and accessible format.

Prashant Gokarn, CEO of DigiAsia, commented, “This partnership with Jalin amplifies our mutual goal of strengthening financial inclusion in Indonesia with ubiquity of financial accessibility in the region. Together, our innovative embedded fintech solutions and Jalin’s ATM asset network platform, will foster financial empowerment for the consumers and merchants of Indonesia, including our network of 1 million merchants. This strategic partnership will drive Indonesia’s commerce and enterprise business growth through widespread digitized finance.”

Ario Tejo Bayu Aji, CEO of Jalin, said, “Combining the distinct core competencies of DigiAsia and Jalin’s businesses bolster the expediency of unlocking financial accessibility to broad communities in Indonesia. We are synergistically paving the way to achieve our aligned social and economic missions. This is evident through the comprehensive robust financial infrastructure of our ATMs and CDMs and DigiAsia’s embedded processes to address the value chain of commerce and enterprises’ ability to achieve growth with its solutions that continue to expedite digitized finance.”

About DigiAsia

DigiAsia is a leading Fintech as a Service (FaaS) provider operating a B2B2X model offering its complete Fintech solution in emerging markets. DigiAsia's fintech architecture offers small and medium business enterprises (SMEs) comprehensive embedded finance APIs to streamline processes across the commerce value chain of distributors and customers. DigiAsia's embedded fintech solutions equally address democratizing digital finance access that supports financial inclusion of underbanked merchants and consumers in emerging markets resulting in growth for enterprise business. The suite of B2B2X solutions provided by DigiAsia include, but are not limited to, cashless payments, digital wallets, digital banking, remittances and banking licenses. DigiAsia has recently established a strategic initiative to develop its embedded FaaS enterprise solution with AI capabilities in Southeast Asia, India, and the Middle East, with plans for global expansion. For more information, please visit DigiAsia’s Corporate website here or Investor Relations website here.

About Jalin

PT Jalin Pembayaran Nusantara (Jalin) is a financial service technology–based company established in 2016 as a result of the joint initiative between the Ministry of State–owned Enterprises, Himbara (Bank Mandiri, BNI, BRI, and BTN), and PT Telkom Indonesia (Persero) Tbk. In 2019, PT Danareksa (Persero), which has transformed into Holding Danareksa, became the majority shareholder of Jalin.

As a company providing integrated service in the sector of modern payment system technology, Jalin manages the LINK switching network services and holds the biggest market share in the debit switching category. Acting as a Payment System Infrastructure Provider (PIP), Jalin begins to transform into a digital enabler that connects the community with financial and non–financial ecosystems, in line with its plan to become “The National Digital Highway”.

Jalin's main services and products focus on the digitalization of banking products, switching services (clearing of ATM cards, debit cards, GPN, and Quick Response Code Indonesian Standard (QRIS)), and virtual ATMs.

Currently, Jalin has more than 60 members from the banking and fintech industries in Indonesia. It is also a member of the Indonesia Payment System Association (ASPI) and a shareholder of PT Penyelesaian Transaksi Elektronik Nasional (PT PTEN) which acts as a Services Institution for GPN.

Forward–Looking Statements:

This press release may contain forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “anticipate”, “project”, “targets”, “optimistic”, “confident that”, “continue to”, “predict”, “intend”, “aim”, “will” or similar expressions are intended to identify forward–looking statements. All statements other than statements of historical fact are statements that may be deemed forward–looking statements. These forward–looking statements including, but not limited to, statements concerning DigiAsia and the Company’s operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. DigiAsia cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world including those discussed in DigiAsia’s Form 20–F under the headings “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business Overview” and other reports filed with the Securities and Exchange Commission from time to time. All forward–looking statements are applicable only as of the date it is made and DigiAsia specifically disclaims any obligation to maintain or update the forward–looking information, whether of the nature contained in this release or otherwise, in the future.

DigiAsia Company Contact:
Subir Lohani
Chief Financial Officer and Chief Strategy Officer
646–480–0142

Investor Contact:
MZ North America
Email: FAAS@mzgroup.us


GLOBENEWSWIRE (Distribution ID 9199341)

AI-first Zoom Docs debuts on Zoom Workplace, enhancing meeting effectiveness and transforming team collaboration, document creation, and project planning

  • Optimize collaboration across Zoom Workplace with next–gen Zoom Docs; transform content from Zoom Meetings into actionable documents with AI Companion
  • Zoom Docs’ AI–first customizable design easily adapts to team and project needs, including documents, wikis, and tables, providing a single place to manage work

SAN JOSE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) announced the rollout of Zoom Docs, its AI–first collaborative docs solution, starting today. Zoom Docs is powered by Zoom AI Companion, the company’s generative AI assistant available at no additional cost*, to help drive productivity and seamless collaboration throughout Zoom Workplace.

“Zoom Docs is our first Zoom Workplace product with generative AI built in from the ground up; it effortlessly transforms information from Zoom Meetings into actionable documents and knowledge bases, so teams can stay focused on meaningful work,” said Smita Hashim, chief product officer at Zoom. “Zoom Docs is included at no additional cost with Zoom Workplace paid licenses, creating even more value for our customers. With AI Companion available every step of the way, Zoom Docs is purpose–built to empower people to ‘work happy’ and give them more time back in their day.”

Zoom Docs transforms team collaboration
Zoom Docs can help solve critical challenges facing modern workforces, including time wasted on repetitive tasks, information overload, and facilitation of cross–functional alignment. By utilizing Zoom AI Companion to convert meeting outcomes into actionable documents, Zoom Docs can jumpstart content creation and adapt to different individual and team needs to help boost workers’ productivity.

Zoom Docs’ AI–first capabilities help Zoom Workplace users make teamwork more collaborative and effective, optimize productivity by keeping information organized, and reduce silos by empowering teams to communicate and share information more fluidly. Potential use cases for Zoom Docs include:

  • Meeting collaboration: Zoom Docs simplifies meeting collaboration with AI Companion by transforming meeting content into meaningful documents, centralizing meeting summaries with meeting docs, and facilitating co–editing on docs within meetings.
  • Business documents: Whether creating content, business proposals, or reports, AI Companion for Zoom Docs makes content generation, revision, summarization, and translation easy for global teams.
  • Project planning: Planning complex projects can be messy. Zoom Docs can help with time–saving templates for project briefs and tracking for a variety of use cases like product launches, marketing campaigns, and event management, consolidating project–related materials, and improving visibility across progress tracking, status updates, and timelines.
  • Information hub: Useful for knowledge–base creation, team onboarding, and goal tracking, users can build robust wikis for a single source of information.

Additional AI–first capabilities help teams do their best work
With the power of AI Companion, Zoom Docs simplifies work and brings information together for optimal results.

  • Turn AI Companion meeting summaries into easily editable docs, freeing up time spent on note–taking and manually copying notes into a shared document with templates for one–on–ones, stand–up meetings, brainstorming, project updates, discussions, Q&As, customer success, user feedback, and more.
  • Generate content based on AI Companion meeting transcripts. Use custom or preset commands or queries with AI Companion to further create and revise content.
  • Revise and summarize content such as articles, plans, and outlines, change tone and style, catch grammatical and spelling errors, and translate content into nine languages (with support for additional languages planned) for multilingual teams with AI Companion.

Maximize meeting effectiveness to drive better outcomes
Meetings are core to Zoom Workplace, and Zoom Docs builds on that experience by enhancing collaboration before, during, and after meetings, empowering users to stay more aligned and achieve better results.

  • Start and schedule meetings from a Zoom Doc to connect with colleagues and quickly streamline workflows.
  • Create, share, and co–edit docs during meetings. Meeting attendees can follow along with the presenter, co–edit, and comment on the doc in real time without leaving the meeting window. Attendees on mobile devices can view in–meeting doc collaboration without signing in.
  • Create an editable and shareable doc that includes relevant meeting information from a meeting in a customizable format.
  • Streamline permission sharing to reduce time spent granting access to docs with bulk permission settings for meeting attendees, and the ability to grant temporary access to meeting attendees to collaborate during the meeting. Users can also share Zoom Docs in Team Chat channels and with individuals in specific chats directly from Zoom Docs.
  • Share docs across Zoom Workplace via Zoom Team Chat or Zoom Mail or invite colleagues to collaborate live in Zoom Meetings to streamline editing.

Get work done in one place for better results
Adapt docs to different individual and team needs to keep collaboration fluid and information organized.

  • Customize docs with content blocks for texts, tables, images, charts, and more to help increase efficiency and reduce information management across multiple apps. Add data tables for team collaboration and planning to track assignments and projects. Add checklists, images, videos, and callouts to make the doc more engaging, and utilize the multi–column layout for greater flexibility in organizing content.
  • Embed content from across Zoom Workplace and third parties like Zoom Whiteboard, Google Drive, Figma, X, and YouTube to make information centrally accessible.
  • Stay organized by starring frequently used docs or quickly filtering docs by author for quick access.

Optimize team collaboration
Reduce silos and keep collaborators informed, connected, and aligned.

  • Keep an eye on progress using tables, checklists, and trackers for activities, due dates, status, and assigned owners, with various views like Kanban boards, calendars, and galleries.
  • Organize team documents in dedicated wikis to provide central locations for shared information.
  • Group, filter, sort, and search data tables to easily visualize information and quickly locate the needed data.
  • Edit concurrently with up to 100 users in a single Zoom Doc, and tag teammates in edits and comments.
  • Quickly add, remove, and change permissions for internal teammates and external users to confidently share and collaborate on a doc’s contents.

Zoom Docs with AI Companion is included with all paid Zoom Workplace plans*. Basic (free) users can create up to 10 shared docs and unlimited personal docs without AI Companion but can upgrade to Zoom Workplace Pro, Business, or Enterprise plans for access to AI Companion capabilities across Zoom Workplace, including Docs. Account owners and admins may enable or disable AI Companion for Zoom Docs.

Zoom Docs is available beginning today for users of the Zoom Workplace app, version 6.1.6 or later, which can be downloaded from the Zoom website, and users can also access Zoom Docs from the Docs web homepage or the Zoom Web App.

*Note: AI Companion is included at no additional cost with the paid services assigned to Zoom accounts. AI Companion, including AI Companion capabilities in Zoom Docs, may not be available for all regions and industry verticals.

About Zoom
Zoom’s mission is to provide one platform that delivers limitless human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer care teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Zoom Public Relations
Lacretia Nichols
press@zoom.us


GLOBENEWSWIRE (Distribution ID 9198845)